GNPX חוב כולל להון Genprex, Inc

Genprex, Inc. (GNPX) is highly regarded by the scientific community for developing breakthrough treatments for diabetes and lung tumors. The company's operations remain independent of market volatility, as demand for therapy is stable and progress is driven by FDA verdicts. This chart illustrates that the market valuation of the total debt-to-equity ratio stands at 0.00. The business relies on the ONCOPREX system, combining gene modifications with immunotherapy to extend patient survival.

An investment audit of Genprex, Inc. (GNPX) requires an analysis of the total liabilities to net equity ratio to assess the business's financial stability. This ratio, available on GURU.Markets, determines the biotech startup's reliance on borrowed funds during the development of the ONCOPREX platform, allowing the debt-to-equity history to identify insolvency risks associated with financing gene therapy.